Advertising

Research
Volume 55, Issue 8, August 2026

Considering the role of shave excision in early melanoma diagnosis

Isabel Gonzalez Matheus    Gabriela Gonzalez Matheus    Daniel Lindsay    Jim Muir   
doi: 10.31128/AJGP-07-25-7744   |    Download article
Cite this article    BIBTEX    REFER    RIS

Background and objectives
Shave excisions are increasingly used in Australian clinical practice for melanoma diagnosis, yet concerns persist regarding margin involvement, diagnostic accuracy and cosmetic outcomes. This study assessed clinician perspectives on the estimated costs, logistics and outcomes of shave versus elliptical excision for melanoma diagnosis.
Methods
An anonymous online survey was distributed to 229 Australian general practitioners and dermatologists involved in skin cancer management. Data on procedure setting, equipment, follow-up, costs and clinical perceptions were analysed.
Results
Clinicians reported shave excision as faster and less resource-intensive than elliptical excision, with higher rates of same-day procedures and reduced follow-up. Median estimated total cost per procedure was $753 for shave excision versus $1473– $1504 for elliptical excision. Users reported favourable cosmetic outcomes and low incidence of deep margin involvement when performed appropriately.
Discussion
Shave excision is likely a cost-saving, diagnostically reliable method for selected lesions. Further prospective research and guideline updates are warranted.
 

Australia has the highest melanoma incidence globally.1 Early diagnosis is associated with improved prognosis and less extensive treatment, as thinner melanomas have a significantly lower risk of metastasis and mortality when compared with thicker lesions.2 Commonly used diagnostic methods include elliptical excision, shave excision and partial biopsies.2 Where possible, complete removal of the lesion is advised to enable accurate histopathological assessment. Partial sampling techniques should generally be avoided, as they risk missing invasive components. Current Australian guidelines recommend elliptical excision with narrow margins as the optimal biopsy technique for suspicious pigmented lesions. However, these recommendations are supported by Level C evidence only (ie the body of evidence provides some support for recommendation/s, but care should be taken in its application).2 Shave excisions are suggested for lesions suspicious for early melanomas.2

Both shave excision and elliptical excision are used with the intent of complete lesion removal, and each has a place in the management of lesions suspicious for melanoma.2 The choice of technique should be guided by lesion characteristics, clinician expertise and patient preferences. Although technically simple, effective shave excisions require adequate training in lesion selection and surgical technique. Shave excision is increasingly used in Australian clinical practice, with utilisation more common among specialist dermatologists.3 Concerns around base transection, histological accuracy and cosmesis are raised by some.4–6 Recent evidence suggests these concerns are likely unfounded given appropriate clinician training, lesion selection and surgical technique.5,7–10 We argue that shave excision is a valid and efficient diagnostic method for thin melanomas, and we summarise key advantages and commonly cited criticisms of shave excision in Table 1.

Table 1. Advantages and criticisms of shave excision in thin lesions suspicious of melanoma diagnosis

Advantage of shave excision when compared with elliptical excision

Evidence-based response

Same-day procedure

Facilitates faster diagnosis, reduces anxiety, increases patient compliance8

Quick and efficient

Takes less time to perform, requires less setup11,12

Facilitates multiple procedures at the same visit13

Minimal equipment

Typically requires only plain lignocaine, scalpel, gauze and dressing9,12

Tissue-conserving

Useful for small or cosmetically sensitive lesions12,13

Rapid turnaround of results

Enables early intervention, which reduces patient anxiety7,8,10

Common criticism

Evidence-based response

Risk of base transection

Extremely rare when performed by skilled clinicians with appropriate lesion selection and technique5,7

Lower diagnostic accuracy

Equivalent accuracy to elliptical excision in multiple studies9,10

Re-excisions are larger

Theoretical only, of little importance on trunk and limbs; most initial excisions are benign and not
re-excised6,12

Poor cosmetic outcomes

In survey data, 80% clinician satisfaction with cosmetic outcomes;13 ellipse remains a revision option if needed

The aim of this study was to assess clinical practice patterns and perceptions related to shave excision versus elliptical excision for early melanoma diagnosis, and to compare estimated procedural costs. The primary objective is to compare the estimated direct and indirect costs associated with each procedure on the basis of real-world clinician input. Shave excision is thought to be less costly, but this has not been well studied. We hypothesised it would be associated with lower costs, reduced equipment use, fewer follow-up visits and high clinician satisfaction when used appropriately.

Methods

We used a cross-sectional descriptive study employing an anonymous online survey to investigate clinician practice patterns, procedural logistics and cost differences between shave excision and elliptical excision for the diagnosis of early melanoma.

An exemption from full ethics review was granted by the Mater Misericordiae Human Research Ethics Committee (Project ID: 115860), in accordance with section 5.1.17 of the National Statement on Ethical Conduct in Human Research (2023).

The survey instrument was developed by the research team, which comprised a specialist dermatologist, prevocational dermatologists and a health economist. The survey focused on the diagnostic management of clinically suspected thin melanoma lesions, where either shave or elliptical excision would be considered acceptable approaches. Survey content was informed by relevant literature, clinical guidelines and procedural experience. Content validity was assessed through expert review, and the instrument was piloted internally to ensure clarity and relevance. The final version consisted of multiple- choice and Likert scale questions, with one free-test response option. The complete survey is provided as Appendix 1 (available online only). 

Participants were Australian general practitioners (GPs) and dermatologists engaged in skin cancer diagnosis and management. Distribution occurred via email through three professional organisations: the Australasian College of Dermatologists, the Skin Cancer College Australasia, and the Australian College of Rural and Remote Medicine. Survey invitations were disseminated with organisational approval through their respective member mailing lists. The survey was open from 10 March to 30 March 2025. GPs without additional skin cancer qualifications were not included, which may limit generalisability.

Responses were collected using Qualtrics and exported to SPSS (Version 29, IBM Corp) for analysis. Only fully completed responses were included. Data were analysed descriptively. Cost estimates were calculated by combining clinician- reported resource use with publicly available pricing data, including Medicare Benefits Schedule (MBS) rebates, medical equipment supplier pricing, and indirect cost estimates such as lost productivity sourced from WorkSafe Australia reports.

Results

A total of 229 completed responses were received. Although a response rate could not be calculated, the number of responses (n = 229) is comparable to other published survey studies involving clinician participants.5,11–14 Most respondents were GPs with formal skin cancer qualifications (n = 119, 52%) or dermatologists (n = 96, 42%). Most participants had more than 10 years of clinical experience in skin cancer management (n = 165, 72%) and reported at least half of their clinical workload involved skin cancer–related activity (n = 195, 85%).

Clinicians were more likely to remove a lesion at the same appointment with a shave (n = 194, 85%) versus elliptical excision (n = 39, 17%). Clinicians were more likely to defer elliptical excisions to a subsequent visit and to perform multiple procedures in a single visit when using shave excision when compared with elliptical excision. Among respondents who reported encountering patients with multiple skin cancers (n = 92), 40% stated they would ‘often’ or ‘always’ perform more than two procedures in the same appointment.

Follow-up requirements also differed by procedure. Only 7% (n = 16) of respondents ‘always’ required a follow-up appointment after shave excision, compared with 98% (n = 293) following elliptical excision with external sutures. Clinicians also reported advising physical activity restrictions far more frequently after elliptical excisions (85%, n = 254 ‘often’ or ‘always’) than after shaves (7%, n = 20).

Clinicians typically reported using minimal equipment for shave excisions — primarily local anaesthetic, a scalpel, haemostatic agent, gauze and a basic dressing. In contrast, elliptical excision required more extensive setup, including sterile suture packs, drapes, absorbable and non-absorbable sutures, and electrocautery in most cases (Table 2).

Table 2. Cost comparison between shave excision and elliptical excision for melanoma diagnosis

 

Direct healthcare costs

Other direct costs

Indirect costs

Total cost

Shave excision

Skin check encounterA = $64

Skin biopsy (MBS item number 30071) = $59.50

Equipment: $4.05

Of the 142 respondents using shave excision, n = 114 (80%) respondents used these items for this procedure: Local anaesthetic ($1.50) + scalpel blade ($0.50) + gauze ($0.50) + haemostatic solution ($1.25) +
dressing ($0.30) = $4.05B

Practice costs per patient per visitC = $55.55

Patient costs per visit:D per day work absenteeism/reduced productivity = $570

Total direct cost (estimate): $127.55

Total indirect cost (estimate): $625.50 (one visit)

Total cost: $753

Elliptical excision

Skin check encounterA = $64

Excision (other than shave) of clinically suspected melanoma (MBS item number 31377–31379) = $124.90–$152.60

Equipment: $44.80

Of the 162 respondents using elliptical excision, n = 147 (91%) respondents used these items for this procedure: Lignocaine with adrenaline ($2.80) + dressing pack ($1.30) + suture pack ($18) + drape ($3) + electrocautery ($5.26) + suture absorbable ($9.70) + suture non absorbable ($4.10) + dressing ($0.70) = $44.80B

Practice costs per patient per visitC = $55.55

Patient costs per visit:D per day work absenteeism/reduced productivity = $570

Total direct cost (estimate): $222–$253

Total indirect cost (estimate): $1251 (two visits)

Total cost: $1473–$1504

A Average cost for MBS Codes 3, 23, 36, 44, 52, 53, 54, 57, 701, 703, 705, 707, 5000, 5020, 5040, 5060, 10990, 10991, 10997 (Professional attendance at consulting rooms by a general practitioner or specialist).

B Equipment prices sourced from https://nationalsurgical.com.au and www.amaproducts.com.au

C Empirical estimates to account for all practice capabilities needed for the delivery of comprehensive care based on published data from the US.18 No Australian data are available.

D Based on an Australian figure from WorkSafe Queensland.

MBS, Medicare Benefits Schedule.

In the MBS, elliptical excisions are billed under items 31377–31383, with rebates ranging from $124.90 to $152.60. Importantly, the wording for MBS items 31377–31383 excludes shave excision from these higher melanoma-specific billing categories. Shave excisions are billed as a biopsy under item 30071 with a rebate of $59.50, a saving when compared with elliptical excision of $65.40–$93.10 per procedure.

Combining direct and estimated indirect costs (including a work absenteeism estimate of $570/day15), the estimated total cost of a shave excision is approximately $753, compared with $1473–$1504 for elliptical excision (Table 2). The cost differential is driven by reduced need for follow-up and time away from work for shave when compared with elliptical excision.

Approximately half (n = 119, 54%) of survey respondents reported employing shave excisions for pigmented lesions suspicious for in situ or thin melanoma. In free-text responses, commonly cited advantages for shave excisions over elliptical excisions included ease of performing the procedure during the same consultation, minimal equipment, reduced follow-up visits, improved workflow efficiency and high patient acceptance (Table 3). Regular users of shave excision reported that margin involvement was not a significant issue when employing appropriate lesion selection and technique.

Table 3. Surveyed ‘pros and cons’ of shave excision

Examples of respondents listing ‘pros’ of shave excision

Examples of respondents listing ‘cons’ of shave excision

‘For the right lesions in experienced hands, it is quick, easy and cost effective.’

‘Given the amount and type of equipment used, I do not find shave excisions to represent a significant time saving compared with elliptical excisions.’

‘Simple, minimal complications, accurate, minimal patient impact, quick.’

‘Shave excisions make a huge mess, hideous scars, and histology specimens often not good enough.’

‘I think it is affordable and time-saving solution compared to elliptical excision and should be used frequently.’

‘I really don’t do these for pigmented lesions. The local pathologists really don’t seem to like it.’

‘Unfathomable to consider a severely sun-damaged patient having no access to shave excision for practical reasons, clinical imperative, clinical urgency and particularly for patient convenience/safety.’

‘I find shaves useful though find them difficult legally to defend because of the melanoma guidelines.’

Clinicians who avoided shave excision (19% reported ‘never’ using) listed perceived suboptimal cosmesis, high risk of base transection and diagnostic uncertainty due to incomplete sampling. Some noted a lack of training or confidence in their ability to perform the technique optimally (Table 3). Apprehension about deviating from clinical guidelines recommending elliptical excision for suspected melanoma was cited as a reason to avoid shave excision. The influence of guidelines on clinical practice in our sample was mixed, with 30% (n = 65) stating the guidelines around the use of elliptical excision were ‘very influential’ on their practice, while 20% (n = 45) indicated they were ‘not influential’. Responding specialist dermatologists were supportive of shave excision, citing comprehensive training in dermoscopy, lesion assessment and procedural techniques as factors enabling confident use. GPs were more likely to never or rarely employ shave excision.

Discussion

Our findings show that shave excision, when used appropriately, is associated with lower procedural costs, reduced equipment needs and fewer follow-up visits when compared with elliptical excision, as well as high clinician acceptability. Despite these benefits, clinician views remain divided, with some expressing concerns about histological accuracy, cosmetic outcomes, and medico- legal risk associated with deviating from existing clinical practice guidelines.

Shave excision is often conflated with shave biopsy,14 a superficial sampling technique, rather than attempted complete excision. When performed with the intent to fully remove a lesion, shave excisions provide adequate tissue for histological assessment and accurate diagnosis. Shave excision of a lesion where melanoma is a significant differential should only be performed when the clinician is confident it can be safely and completely removed in width and depth. Recent prospective Australian data of over 300 shave-excised pigmented lesions, including 50 melanomas, found no deep margin transection when performed by trained clinicians.7 Lateral margin involvement was equivalent to elliptical excision. While elliptical excision allows for easier specimen orientation, this is generally not a limiting factor in shave excision, as definitive management typically involves subsequent wide local excision.

Shave excision yields a higher proportion of in situ melanomas than invasive, suggesting that it may facilitate earlier detection.12,13 A recent review found no significant difference in diagnostic accuracy or margin involvement of shave when compared with elliptical excision.9 Further, 80% of dermatologists and GPs who regularly used shave excision were satisfied with the cosmetic results.13 Concerns about scarring apply to both shave and elliptical procedures. No studies have specifically asked patients about their satisfaction with cosmetic outcomes following shave versus elliptical excision, representing an important area for further research.

The ability to promptly remove multiple suspect lesions may help alleviate patient anxiety by ensuring that potentially cancerous lesions are addressed without delay and can be sent for histopathological assessment sooner. Our survey revealed that elliptical excision is uncommonly a same-day procedure, in contrast to shave excision. Rescheduling procedures to another day places a logistical and medico-legal burden on practitioners.14 Compliance is virtually guaranteed with same-day shave excision. Further research exploring patient perspectives on shave and elliptical excision could provide valuable insights and help inform future clinical recommendations.

Skin cancers collectively impose the highest economic burden of all cancers on the Australian healthcare system.16,17 As the diagnosis of skin cancer, particularly thin and in situ melanoma, continues to increase in Australia, it is essential to evaluate the economic impact of diagnostic procedures. Identifying cost-saving methods that do not compromise clinical care can help mitigate financial burdens in a resource- restrained healthcare system and ensure more sustainable healthcare practices. We have shown that shave excisions are likely a cost-saving diagnostic method when compared with elliptical excision. The cost estimates were based on clinician-reported practice patterns, including follow-up visits, and applied consistently across both procedures using uniform sources for comparison. Result discussions following shave excision were commonly conducted remotely, with no follow-up visit required in the majority of cases.

From a national perspective, 15,628 melanomas were diagnosed in Australia in 2019.16 Using the results from a Queensland cohort,3 67% of these melanomas were melanoma in situ (n = 10,471). Of the remaining invasive melanomas (n = 5157), 69% were <1 mm in thickness (n = 3559). The majority of in situ and thin invasive melanomas diagnosed in Australia could have been initially managed using shave excision. Had the estimated number of in situ or thin invasive melanomas (approximately 14,029 cases) diagnosed in Australia in 2019 been managed with shave excision, the total cost would be approximately $10.5 million, based on our estimated cost of $753 per procedure. In contrast, management with elliptical excision at a cost of $1473–$1504 per case would produce estimated total costs of $20.6–$21.1 million. Widespread shave excision use represents a potential cost saving of approximately $10–11 million annually. Given the assumptions of our cost estimates, these values should be interpreted with caution until more detailed costing studies are performed.

This study has limitations. The survey was based on self-reported practices, which are subject to bias. However, self-reported responses allowed us to highlight the opposing views of Australian clinicians on the use of shave excision in clinical practice. Out-of-pocket costs were not included in our analysis because of their variability and the difficulty in obtaining reliable data. We also acknowledge that the use of a full day of work absenteeism for follow-up visits may overestimate productivity loss in some cases. Our costings were based on estimated values, with more detailed costing studies required to better quantify the total costs for shave and elliptical excision procedures.

Cost is only one consideration among many in melanoma diagnosis, and further studies assessing patient outcomes will be critical to complement economic findings. We also acknowledge that lesion-specific factors such as anatomical site may influence the choice of biopsy technique, cost and clinical outcomes. However, our study was designed to assess broader patterns in clinical practice.

Despite benefits in terms of cost and time savings and demonstrable safety, a proportion of Australian clinicians remain reluctant to perform shave excisions. This may be driven by current Australian melanoma guidelines, which recommend elliptical excision for initial diagnosis on the basis of Level C evidence only. Current clinical guidelines should be updated to reflect the widespread and increasing use of shave excision and the ample data supporting its relative utility, efficiency, lower cost and safety.

Conclusion

Shave excision is increasingly and effectively used in clinical practice, particularly among specialist dermatologists. Our real-world data highlight the practicality of shave excisions, including the ability to perform procedures on the same day with minimal equipment requirements, a reduced need for follow-up appointments for wound management or suture removal, and a reduction in both estimated direct medical costs and indirect costs such as time off work when compared with elliptical excision. Shave excision also facilitates the treatment of multiple lesions in a single visit, an important consideration in a region with the highest incidence of skin cancer in the world. Given the available evidence and positive views of regular users of shave excision, familiarisation with and training in the technique may dispel the concerns of those who rarely or never employ shave excisions, particularly among GPs.

Competing interests: None.
AI declaration: The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript.
Provenance and peer review: Not commissioned, externally peer reviewed.
Funding: None.
Correspondence to:
isabel.gonzalezmatheus@health.qld.gov.au

This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log
References
  1. Gordon LG, Elliott TM, Olsen CM, Pandeya N, Whiteman DC. Multiplicity of skin cancers in Queensland and their cost burden to government and patients. Aust N Z J Public Health 2018;42(1):86–91. doi: 10.1111/1753-6405.12738. Search PubMed
  2. Sladden MJ, Nieweg OE, Howle J, Coventry BJ, Thompson JF. Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: Definitive excision margins for primary cutaneous melanoma. Med J Aust 2018;208(3):137–42. doi: 10.5694/mja17.00278. Search PubMed
  3. Pandeya N, Olsen CM, Shalit MM, Dusingize JC, Neale RE, Whiteman DC. The diagnosis and initial management of melanoma in Australia: Findings from the prospective, population-based QSkin study. Med J Aust 2023;218(9):402–07. doi: 10.5694/mja2.51919. Search PubMed
  4. Martires KJ, Nandi T, Honda K, Cooper KD, Bordeaux JS. Prognosis of patients with transected melanomas. Dermatol Surg 2013;39(4):605–15. doi: 10.1111/dsu.12124. Search PubMed
  5. de Menezes SL, Kelly JW, Wolfe R, Farrugia H, Mar VJ. The increasing use of shave biopsy for diagnosing invasive melanoma in Australia. Med J Aust 2019;211(5):213–18. doi: 10.5694/mja2.50289. Search PubMed
  6. Ahmadi O, Das M, Hajarizadeh B, Mathy JA. Impact of shave biopsy on diagnosis and management of cutaneous melanoma: A systematic review and meta-analysis. Ann Surg Oncol 2021;28(11):6168–76. doi: 10.1245/s10434-021-09866-3. Search PubMed
  7. Shao E, Blake T, Po-Chao F, et al. Prospective study of pigmented lesions managed by shave excision with no deep margin transection of melanomas. Australas J Dermatol 2020;61(3):269–72. doi: 10.1111/ajd.13312. Search PubMed
  8. Yousif J, Alkhouri F, St Claire K, Potts G. A practical guide to reducing preoperative and intraoperative patient anxiety in dermatologic surgery. Int J Dermatol 2023;62(9):1154–59. doi: 10.1111/ijd.16802. Search PubMed
  9. Jones S, Henry V, Strong E, et al. Clinical impact and accuracy of shave biopsy for initial diagnosis of cutaneous melanoma. J Surg Res 2023;286:35–40. doi: 10.1016/j.jss.2022.12.042. Search PubMed
  10. Kaufman J, et al. The accuracy of shave excision for melanoma diagnosis: A review. J Am Acad Dermatol 2014;71(3):470–75. Search PubMed
  11. Blundo A, Cignoni A, Banfi T, Ciuti G. Comparative analysis of diagnostic techniques for melanoma detection: A systematic review of diagnostic test accuracy studies and meta-analysis. Front Med (Lausanne) 2021;8:637069. doi: 10.3389/fmed.2021.637069. Search PubMed
  12. Gonzalez Matheus G, Robins CP, Muir J. Guide to shave procedures in general practice. Aust J Gen Pract 2024;53(6):398–402. doi: 10.31128/AJGP-06-23-6872. Search PubMed
  13. Pitney T, Muir J. The use of shave excision by dermatologists in Australia: A consensus survey. Australas J Dermatol 2021;62(4):514–17. doi: 10.1111/ajd.13664. Search PubMed
  14. Lindsay D, Collins LG, Olsen CM, et al. Factors influencing the use of shave biopsy for lesions suspicious of melanoma in Australia: An exploratory mixed-methods study. Australas J Dermatol 2025;66(1):e1–9. doi: 10.1111/ajd.14411. Search PubMed
  15. WorkCover Queensland. Private hospital services: Table of costs. WorkCover Queensland, 2025. Available at www.worksafe.qld.gov.auf [Accessed 17 June 2026]. Search PubMed
  16. Australian Government, Cancer Australia. Melanoma of the skin statistics. Australian Government, Cancer Australia, 2025. Available at www.canceraustralia.gov.au [Accessed 23 April 2025]. Search PubMed
  17. Guitera P, Menzies SW, Coates E, et al. Efficiency of detecting new primary melanoma among individuals treated in a high-risk clinic for skin surveillance. JAMA Dermatol 2021;157(5):521–30. doi: 10.1001/jamadermatol.2020.5651. Search PubMed
  18. Martsolf GR, Kandrack R, Friedberg MW, Briscombe B, Hussey PS, LaBonte C. Estimating the costs of implementing comprehensive primary care: A narrative review. Health Serv Res Manag Epidemiol 2019;6:2333392819842484. doi: 10.1177/2333392819842484. Search PubMed

Health economicsMelanomaShave excisionSkin cancer

Download article